Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rockefeller Generic Rx Bill Would Penalize Brands For Failed Patent Defense

Executive Summary

Generic drug legislation floated by Sen. Jay Rockefeller (D-W.Va.) would create a drug reimbursement fund to compensate parties denied access to generic drugs due to litigation

You may also be interested in...



FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation

The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation

FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation

The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation

“Orange Book” Certifications Would List Patent Claims Under Rockefeller Bill

"Orange Book" patent certifications would include an enumeration of the relevant claims under generic drug reform legislation introduced by Sen. Jay Rockefeller (D-W.Va.)

Related Content

UsernamePublicRestriction

Register

PS040062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel